Merck & Co. (NYSE:MRK) shares traded lower on Tuesday, tracking a broader market downturn as major indices slipped into the red.

The company said it has commenced a cash tender offer, through a subsidiary, to acquire all outstanding shares of Terns Pharmaceuticals Inc. (NASDAQ:TERN). The offer follows a definitive agreement announced March 25, 2026.

Under the terms, Merck is offering $53.00 per share in cash for Terns. The tender offer is set to expire May 4, 2026, subject to customary conditions, including shareholder participation thresholds and regulatory approvals.

The broader market is experiencing a downturn, with the S&P 500 down 0.9% and the Healthcare sector also facing a decline of 0.5%.

Technical Analysis

At $117.40, the stock is trading slightly above its 20-day simple moving average (SMA) by 0.04%, indicating a neutral short-term trend. However, it is trading 0.1% below its 50-day SMA, suggesting some weakness in the intermediate trend.

The relative strength index (RSI) is at 61.12, which is neutral, indicating that the stock is neither overbought nor oversold at this time. The moving average convergence divergence (MACD) shows a bullish signal, with the MACD line at 0.9163 above the signal line at 0.4374, suggesting upward momentum.

  • Key Resistance: $125.00 — This level may act as a barrier for upward movement.
  • Key Support: $114.00 — A drop below this level could indicate further selling pressure.

The stock has performed well over the last 12 months, gaining 44.67%, reflecting strong long-term momentum. Currently, it is trading near its 52-week high of $125.14, which suggests a bullish sentiment among investors.

Sector Performance

Merck is part of the Healthcare sector, which is currently ranked 6 out of 11 sectors, reflecting a mid-tier performance. Today, the sector is down 0.49%, indicating that the overall environment is challenging for healthcare stocks. Over the past 30 days, the sector has declined by 5.64%, and over the last 90 days, it has dropped by 8.83%, suggesting a longer-term trend of weakness.

Despite the sector’s struggles, Merck’s recent news regarding the acquisition of Terns Pharmaceuticals may provide a strategic growth opportunity, although it is currently underperforming relative to the sector by 2.36 percentage points.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm’s immuno-oncology platform, led by Keytruda, is a major contributor to overall sales.

The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company’s sales are generated from U.S. human health (pharmaceuticals and vaccines).

Earnings & Analyst Outlook

Merck is slated to provide its next financial update on April 30, 2026 (confirmed).

  • EPS Estimate: -101 cents (Down from 222 cents)
  • Revenue Estimate: $15.93 Billion (Up from $15.53 Billion)
  • Valuation: P/E of 16.6x (Indicates fair valuation)

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $122.22. Recent analyst moves include:

  • JP Morgan: Overweight (Raises Target to $135.00) (April 6)
  • RBC Capital: Outperform (Maintains Target to $142.00) (March 30)
  • Citigroup: Neutral (Raises Target to $125.00) (March 20)

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Merck, highlighting its strengths and weaknesses compared to the broader market:

  • Value: 4.02 — Indicates a weak value proposition relative to peers.
  • Growth: 60.55 — Suggests moderate growth potential.
  • Quality: 61.82 — Reflects a solid quality profile.
  • Momentum: 83.85 — Indicates strong momentum in the stock.

The Verdict: Merck’s Benzinga Edge signal reveals a balanced profile with strong momentum but weak value, suggesting a focus on growth opportunities while navigating current market challenges.

Top ETF Exposure

  • First Trust Morningstar Dividend Leaders Index Fund (NYSE:FDL): 5.50% Weight
  • VanEck Pharmaceutical ETF (NASDAQ:PPH): 8.90% Weight
  • Invesco Dow Jones Industrial Average Dividend ETF (NYSE:DJD): 8.90% Weight

Significance: Because MRK carries such a heavy weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.

Price Action

MRK Price Action: Merck shares were down 3.12% at $117.08 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo by Tada Images via Shutterstock